GlobeNewsWire
18 Jun 2026, 12:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of a channel-stuffing scheme to report 20% revenue growth in 2025 when actual growth was allegedly -3%. — Allegations of systemic financial manipulation and artificial revenue inflation typically lead to severe valuation resets and loss of investor trust.
-0.90Berger Montague PC has filed a class action lawsuit against ADMA Biologics on behalf of investors for the period from August 9, 2024, through March 25, 2026. — Class action lawsuits introduce significant legal liability and potential settlement costs, further weighing on the stock price.
-0.50The lawsuit alleges that ADMA Biologics failed to disclose related party transactions involving a distributor. — Lack of transparency regarding related party transactions suggests governance failures and potential conflicts of interest.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is the subject of a class action lawsuit announced by Berger Montague.
The company is facing a class action lawsuit alleging a channel-stuffing scheme to inflate revenue growth.
The company is the subject of a class action lawsuit announced by Berger Montague.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
48m ago
